TABLE OF CONTENTS
Volume 11, Issue 1 (October 2004)
Editorial
Editorial: Are clinical trial authorisations truly being harmonised?
Linda R Horton
J Commer Biotechnol 11: 5-8; doi:10.1057/palgrave.jcb.3040097
Papers
Bioentrepreneurship in Japan: Institutional transformation and the growth of bioventures
Michael J Lynskey
J Commer Biotechnol 11: 9-37; doi:10.1057/palgrave.jcb.3040098
Changes to the European Union pharmaceutical legislation: Implications of the 'Pharma Review' for biotechnology companies
Erkki Liikanen
J Commer Biotechnol 11: 38-43; doi:10.1057/palgrave.jcb.3040099
A brave new Europe with the introduction of the EU Clinical Trials Directive: Impact upon the pharma industry and academic research with special emphasis on pharmacovigilance
Graeme Ladds
J Commer Biotechnol 11: 44-53; doi:10.1057/palgrave.jcb.3040100
Interference basics
Thomas J Kowalski, William F Lawrence and Samuel H Megerditchian
J Commer Biotechnol 11: 54-62; doi:10.1057/palgrave.jcb.3040101
Where will industry go to for its high-calibre staff?
Faiz Kermani and Rebecca Gittins
J Commer Biotechnol 11: 63-71; doi:10.1057/palgrave.jcb.3040102
Cross-border transactions: A roadmap for commercial arrangements between North American and European companies
Raymond S Fersko, Hind Merabet and Valentina Cordioli
J Commer Biotechnol 11: 72-79; doi:10.1057/palgrave.jcb.3040103
Biotech blockbuster forecasts to 2008
Alex K Pavlou BSc, MSc, PhD and Mark Belsey
J Commer Biotechnol 11: 80-86; doi:10.1057/palgrave.jcb.3040104
Miscellaneous
Regulatory data protection for medicines
John Wilkinson and Frederick J Dorey
J Commer Biotechnol 11: 87-96; doi:10.1057/palgrave.jcb.3040105
